부산대학교 도서관

We administered NY-198, a new pyridonecarboxylic acid synthetic antibacterial agent, to 20 patients with mild or moderate respiratory tract infection (RTI). In addition, we investigated the degree of accumulation of the drug during continuous administration for 7-14 days, and measured its concentration in blood from samples collected after the first and final doses. The following results were obtained.1) NY-198 was orally administered to 17 patient's with bronchitis and 3 with pneumonia. The dose was 200 mg/day in one patient and 400 mg/day in the other 19 patients. Evaluation of clinical effect showed an efficacy rate of 85%.2) Causative bacteria were isolated in six cases, and eradication of these was achieved in three.3) There were no striking side-effects or abnormal laboratory test values.4) Following administration of the first dose of NY-198, peak concentration of the drug in serum occurred 1 h after ingestion. In contrast, the peak value was detected 4 h after the final oral dose, and there was thus adelay in the appearance of the highest serum concentration. Nevertheless, there was little difference between these peak values, indicating no significant accumulation of NY-198 even in continuous administration.